EARS Auris Medical Holding AG

0.44
-0.02  -4%
Previous Close 0.45
Open 0.46
Price To Book -14.5
Market Cap 13004554
Shares 29,895,527
Volume 966,759
Short Ratio
Av. Daily Volume 8,075,449

SEC filingsSee all SEC filings

  1. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181232240
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181232227
  3. 424B3 - Prospectus [Rule 424(b)(3)] 181227853
  4. 424B3 - Prospectus [Rule 424(b)(3)] 181227851
  5. 424B3 - Prospectus [Rule 424(b)(3)] 181227846

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Open label safety trial data released April 24, 2017 and May 9, 2017.
Keyzilen (AM-101) - AMPACT open-label
Acute inner ear tinnitus
Phase 3 HEALOS trial did not meet primary endpoint - November 28, 2017.
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3 data released March 13, 2018 - primary endpoint not met.
Keyzilen (AM-101) - TACTT3
Acute inner ear tinnitus
Phase 3 ASSENT trial terminated - November 28, 2017.
AM-111 ASSENT
Acute inner ear hearing loss
Phase 2 trial (REACH) enrollment pending funding.
AM-111 REACH
Surgery-induced hearing loss
Phase 3 trial did not meet primary endpoints
AM-101 (Keyzilen) - TACTT2
Acute inner ear tinnitus
Phase 1 data released October 17, 2018 with Phase 2 trials to commence 1Q 2019.
AM-125
Vertigo

Latest News

  1. New Healthcare Trends Pushing Stocks Higher On Thursday
  2. Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine
  3. Biotech and Cannabis Stocks to Watch
  4. Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication — What Drives Growth in Today's Competitive Landscape
  5. Today's Research Reports on Trending Tickers: Auris Medical and Bioblast Pharma
  6. Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program in Olanzapine-Induced Weight Gain
  7. Auris: 3Q Earnings Snapshot
  8. Auris Medical Reports Third Quarter 2018 Financial Results and Provides Business Update
  9. Auris Medical to Report Third Quarter 2018 Financial Results and Provide Business Update on Thursday, November 15, 2018
  10. Today's Research Reports on Trending Tickers: Loxo Oncology and Auris Medical Holding
  11. Edison issues initiation on Auris Medical Holding (EARS)
  12. Auris Medical Announces Positive Results From Second Phase 1 Clinical Trial With Intranasal Betahistine
  13. Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Agile Therapeutics
  14. Why Auris Medical Stock Is Soaring Today
  15. Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018
  16. Auris Medical Shares Gain on Initiated Coverage, Analysts Review and Target
  17. Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Menlo Therapeutics

SEC Filings

  1. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181232240
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181232227
  3. 424B3 - Prospectus [Rule 424(b)(3)] 181227853
  4. 424B3 - Prospectus [Rule 424(b)(3)] 181227851
  5. 424B3 - Prospectus [Rule 424(b)(3)] 181227846
  6. 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 181227841
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181209957
  8. 424B3 - Prospectus [Rule 424(b)(3)] 181209950
  9. 424B3 - Prospectus [Rule 424(b)(3)] 181209944
  10. 424B3 - Prospectus [Rule 424(b)(3)] 181209938